Thomson Reuters Corp. said Monday it has acquired a company called GeneGo that supplies data and analysis for pharmaceutical research and development. Terms were not disclosed.
GeneGo is aimed at helping pharmaceutical, biotechnology, and academic research groups understand the genetic mechanisms of diseases and potential treatments.
Thomson said the business will be integrated into its Healthcare & Science division.
The healthcare and science division is a part of Thomson Reuters' larger Professional segment, which has emerged as the faster growing half of the company coming out of the recession. The company's Markets division, which includes trading terminals and the Reuters news service, was harder hit by the downturn as financial companies shed jobs and has recovered more slowly.
No comments:
Post a Comment